103694-26-4

Basic information

• Product Name: C-(2-METHYL-THIAZOL-4-YL)-METHYLAMINE
• Synonyms: RARECHEM AL BW 0694;4-AMINOMETHYL-2-METHYL-1,3-THIAZOLE;2-METHYL-1,3-THIAZOLE-4-METHYLAMINE;C-(2-METHYL-THIAZOL-4-YL)-METHYLAMINE;CHEMBRDG-BB 4101061;(2-methyl-1,3-thiazol-4-yl)methylamine;(2-METHYLTHIAZOL-4-YL)METHYLAMINE;1-(2-methyl-1,3-thiazol-4-yl)methanamine(SALTDATA: 2HCl)
• CAS NO: 103694-26-4
• Molecular Formula: C₅H₈N₂S
• Molecular Weight: 128.2
• Product Categories: Aminomethyl's;Thiazoles, Isothiazoles &Benzothiazoles;Thiazoles, Isothiazoles & Benzothiazoles
• Mol File: 103694-26-4.mol

Chemical Properties

• Boiling Point: 221.4 °C at 760 mmHg
• Flash Point: 87.7 °C
• Appearance: /
• Density: 1.182 g/cm³
• Vapor Pressure: 0.107mmHg at 25°C
• Refractive Index: 1.578
• PKA: 7.65±0.29(Predicted)
• CAS DataBase Reference: C-(2-METHYL-THIAZOL-4-YL)-METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: C-(2-METHYL-THIAZOL-4-YL)-METHYLAMINE(103694-26-4)
• EPA Substance Registry System: C-(2-METHYL-THIAZOL-4-YL)-METHYLAMINE(103694-26-4)

Safety Data

• Hazard Codes: C,Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 103694-26-4(Hazardous Substances Data)

Usage

Uses

Used in Scientific Research and Studies:
C-(2-METHYL-THIAZOL-4-YL)-METHYLAMINE is utilized as a research compound for its unique properties and potential applications in various scientific fields. Its role in these studies is to provide insights into the behavior and interactions of Thiazoles and their derivatives, contributing to the understanding of their chemical and biological properties.
Used in Pharmaceutical Development:
In the pharmaceutical industry, C-(2-METHYL-THIAZOL-4-YL)-METHYLAMINE may be employed as a building block or intermediate in the synthesis of new drug molecules. Its unique structure and properties could be leveraged to develop novel therapeutic agents with specific target interactions and biological activities.
Used in Chemical Synthesis:
C-(2-METHYL-THIAZOL-4-YL)-METHYLAMINE can be used as a reagent or intermediate in the synthesis of various organic and inorganic compounds. Its ability to form stable complexes and participate in different chemical reactions makes it a valuable component in the development of new materials and products.
Used in Analytical Chemistry:
In analytical chemistry, C-(2-METHYL-THIAZOL-4-YL)-METHYLAMINE may be employed as a reference compound or standard for the development and validation of analytical methods. Its unique properties can be used to assess the performance of instruments and techniques in detecting and quantifying similar compounds.

InChI:InChI=1/C5H8N2S/c1-4-7-5(2-6)3-8-4/h3H,2,6H2,1H3

Upstream product

• 100382-11-4 2-((2-methylthiazol-4-yl)methyl)isoindoline-1,3-dione 
• 39238-07-8 4-(chloromethyl)-2-methyl-1,3-thiazole 
• 838893-01-9 (2-methylthiazol-4-ylmethyl)carbamic acid 2-trimethylsilanylethyl ester 
• 802868-31-1 1-((1-aminoethyl)thio)-3-chloropropan-2-one 

Downstream Products

• 102166-64-3 N-acetyl-4-[bis-(2-chloro-ethyl)-amino]-phenylalanine (4-methyl-thiazol-2-ylmethyl)-amide 
• 1191988-25-6 N₃-cyclopropyl-5-fluoro-6-methyl-N₄'-[(2-methyl-1,3-thiazol-4-yl)methyl]-3,4'-biphenyldicarboxamide 

Relevant articles and documents

MACROCYCLES AS PDE1 INHIBITORS

The present invention provides macrocycles of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS

The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor.